Escobar-Morreale H F, Bravo P, García-Robles R, García-Laraña J, de la Calle H, Sancho J M
Department of Endocrinology, Hospital Ramón y Cajal, Madrid, Spain.
Thyroid. 1997 Feb;7(1):67-70. doi: 10.1089/thy.1997.7.67.
Aplastic anemia is a rare but severe complication of thionamide therapy. Although colony-stimulating factors have been used extensively in thionamide-induced agranulocytosis with good results, the same might not apply to aplastic anemia. We present a case of a patient with methimazole-induced aplastic anemia in which, as administration of recombinant human granulocyte-monocyte colony-stimulating factor for a week did not result in an increase in peripheral blood cell count, standard immunosuppressive treatment was needed to restore normal hematopoiesis. The clinical characteristics of this patient are compared with those of previous cases of thionamide-induced aplastic anemia, especially with the only other reported patient in which colony-stimulating factors were used.
再生障碍性贫血是硫代酰胺类药物治疗罕见但严重的并发症。尽管集落刺激因子已广泛用于硫代酰胺类药物诱导的粒细胞缺乏症且效果良好，但对再生障碍性贫血可能并不适用。我们报告一例甲巯咪唑诱导的再生障碍性贫血患者，该患者接受重组人粒细胞-单核细胞集落刺激因子治疗一周后外周血细胞计数未增加，因此需要标准免疫抑制治疗来恢复正常造血。将该患者的临床特征与先前硫代酰胺类药物诱导的再生障碍性贫血病例进行比较，特别是与另一例唯一报道使用集落刺激因子的患者进行比较。
